RECRUITING

Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)

Description

The reason for this research study is to better understand the use of liraglutide, a commonly prescribed Type 2 diabetes medication, in patients with a diagnosis of maturity-onset diabetes of the young (MODY). The investigators are interested in better understanding the way that this drug affects the metabolism and hormone levels of a person with MODY. Many people with MODY report having gastrointestinal (GI) issues such as an upset stomach. Investigators also interested in finding out if this drug will help with GI issues. If liraglutide does help with this symptom of MODY, the investigators want to know why this happens. If this drug is effective for participants, the investigators will use participants cells to make human induced pluripotent stem cell (iPSC). This means that the investigators will use participant cells to create what are called stem cells, which are cells in the body that are able to be told what their job is. Investigators will use these cells to see what happens in gastrointestinal (GI) tract.

Study Overview

Study Details

Study overview

The reason for this research study is to better understand the use of liraglutide, a commonly prescribed Type 2 diabetes medication, in patients with a diagnosis of maturity-onset diabetes of the young (MODY). The investigators are interested in better understanding the way that this drug affects the metabolism and hormone levels of a person with MODY. Many people with MODY report having gastrointestinal (GI) issues such as an upset stomach. Investigators also interested in finding out if this drug will help with GI issues. If liraglutide does help with this symptom of MODY, the investigators want to know why this happens. If this drug is effective for participants, the investigators will use participants cells to make human induced pluripotent stem cell (iPSC). This means that the investigators will use participant cells to create what are called stem cells, which are cells in the body that are able to be told what their job is. Investigators will use these cells to see what happens in gastrointestinal (GI) tract.

Investigating Enteroendocrine Dysfunction, Metabolism, and Response to Liraglutide in Patients With Maturity-onset Diabetes of the Young (MODY)

Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)

Condition
Maturity Onset Diabetes of the Young
Intervention / Treatment

-

Contacts and Locations

Cincinnati

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States, 45229

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Diagnosis of MODY via genetic testing
  • * HgbA1c \>6.5%
  • * History of anaphylaxis to GLP-1 receptor agonists
  • * Already taking GLP-1 receptor agonists
  • * on medications within the stimulant class
  • * have had bariatric surgery
  • * personal or family history of cancer, especially medullary thyroid cancer
  • * personal history of pancreatitis or pathogenic variants associated with increased risk of pancreatitis
  • * known active kidney disease
  • * severe hypoglycemia (glucose \< 50 mg/dL) within 3 months of study enrollment
  • * HbA1c \> 10.0%
  • * episode of diabetic ketoacidosis (DKA) in the past 3 months
  • * are currently pregnant
  • * BMI \< 18.5 kg/m2 and pediatric patients with BMI \< 5th percentile

Ages Eligible for Study

10 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Mansa,

Mansa Krishnamurthy, M.D., PRINCIPAL_INVESTIGATOR, Children's Hospital Medical Center, Cincinnati

Study Record Dates

2027-01